STOCK TITAN

Alkermes plc. (ALKS) SEC Filings, Aug-Sep 2026

ALKS NASDAQ

Alkermes plc filings document a Nasdaq-listed Irish public limited biopharmaceutical company focused on neuroscience medicines. The record includes 8-K reports for operating results, financial expectations, investor presentations, material definitive agreements and Regulation FD disclosures, along with proxy materials for annual general meeting matters, director elections, executive compensation and shareholder voting.

Capital-structure disclosures cover ordinary shares listed under ALKS and senior secured term loan facilities used in connection with completed acquisition activity. Material-event reports also address governance and executive transition matters, compensatory arrangements, commercial-product performance and clinical-stage disclosures for the company’s orexin 2 receptor agonist programs.

Rhea-AI Summary

Alkermes plc. (ALKS) filed an initial statement of beneficial ownership reporting that Anne Clem Whitaker is a director of the company. The filing does not list any securities transactions or current holdings and includes an exhibit for a Power of Attorney.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.82%
Tags
insider
-
Rhea-AI Summary

Alkermes plc (ALKS) reported that its board of directors increased in size from ten to eleven members and appointed Anne C. Whitaker as an independent director effective September 14, 2026, with an initial term expiring at the 2027 annual general meeting of shareholders. For her board service, she will receive cash and equity compensation consistent with the company’s standard director program. In connection with her appointment, she is expected to receive in October 2026 a new director equity award with an aggregate target value of $600,000, split 50% stock options and 50% restricted stock unit awards, vesting in three equal annual installments starting on the first anniversary of grant, subject to continuous service. Alkermes also entered into indemnification arrangements with Ms. Whitaker and issued a press release on September 16, 2026, announcing her appointment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.09%
Tags
current report
-
Rhea-AI Summary

Alkermes plc. (ALKS) reported that executive vice president and chief legal officer David Joseph Gaffin sold 2,034 Ordinary Shares on September 3, 2026 at $48.01 per share in a market transaction. After this sale, he holds 223,422 Ordinary Shares directly, and the transaction was made under a Rule 10b5-1 trading plan adopted on November 19, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.66%
Tags
insider
Rhea-AI Summary

Alkermes plc officer David Gaffin gave notice of a proposed sale of 2,034 common shares, with an aggregate market value of $97,652.34 and an approximate sale date of September 3, 2026. Merrill Lynch is named as broker. The notice records November 19, 2025, as the date of plan adoption or giving of instruction in the Rule 10b5-1 field.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.66%
Tags
other
-
Rhea-AI Summary

Alkermes plc (ALKS) reported insider activity by Craig C. Hopkinson, EVP R&D and Chief Medical Officer. On 2026-09-01, he exercised 5,000 Employee Stock Options at an exercise price of $24.59 per share to acquire 5,000 Ordinary Shares, and sold 9,000 Ordinary Shares at a weighted average price of $46.986 per share. The option exercise and sale were effected pursuant to a Rule 10b5-1 trading plan adopted on 2025-03-14. After the option exercise, he held 61,276 stock options of this grant, which are fully vested in accordance with their terms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.10%
Tags
insider
-
Rhea-AI Summary

Alkermes plc. (ALKS) received a Rule 144 notice from officer Craig C. Hopkinson covering potential sales of its ordinary shares. The notice lists 9,000 ordinary shares held at Merrill Lynch and an issuer share count of 167,763,272 ordinary shares outstanding as of 09/01/2026.

Shares to be sold include 5,000 shares from an employee stock option exercise on 09/01/2026, 1,898 shares from vesting of a performance share award on 02/05/2026, and 2,102 shares from vesting of restricted stock units on 02/23/2026. The filing also lists several prior sales of 9,000-share blocks between March and August 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.10%
Tags
other
Rhea-AI Summary

Alkermes plc. SVP and Chief Commercial Officer Christian Todd Nichols reported open-market sales of Alkermes ordinary shares. On 2026-08-17, he sold 6,912 shares at a weighted average price of $49.1851 and 664 shares at a weighted average price of $49.6526, in transactions made under a Rule 10b5-1 trading plan. Each sale was executed through multiple trades within disclosed price ranges.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
insider
-
Rhea-AI Summary

Alkermes plc has a beneficial owner planning to sell 7,576 shares of common stock through Merrill Lynch on NASDAQ. The proposed sale has an aggregate market value of $372,936.86 and is scheduled on or after August 17, 2026.

The seller previously acquired Alkermes common stock through vesting of restricted stock unit awards, including 2,473 shares on February 23, 2025, 3,952 shares on February 22, 2025, and 1,151 shares on February 18, 2025 under the issuer’s equity compensation plan.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
other
-
Rhea-AI Summary

Alkermes plc entered into Amendment No. 1 to its existing senior secured credit agreement, which governs a term loan A facility and a term loan B facility. The term loan A facility has an outstanding principal amount of $745,312,500 and matures on February 12, 2031, while the term loan B facility has an outstanding principal amount of $773,062,500 and matures on August 12, 2031.

The amendment reduces the interest rate spread on these facilities, lowering the spread on the term loan A facility by 0.75% and on the term loan B facility by 0.50%. After the changes, borrowings under the term loan A facility bear interest at either the Term SOFR Rate plus a Secured Net Leverage Ratio-based margin of 1.75%–2.25% per year, or the Alternate Base Rate plus a margin of 0.75%–1.25%. Borrowings under the term loan B facility bear interest at either the Term SOFR Rate plus 2.25% per year or the Alternate Base Rate plus 1.25%, at the company’s option.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.17%
Tags
current report
Rhea-AI Summary

Alkermes plc reported that President & CEO Jackson Blair Curtis received two grants of Employee Stock Options on 2026-08-05. One award covers 93,229 options with an exercise price of $49.6100 per share, vesting in four equal annual installments commencing on 8/5/2027 and expiring on 2036-08-05. A second award covers 124,305 options at the same exercise price and expiration, vesting in two tranches only if Alkermes’s ordinary share trades at certain pre-specified price levels for 30 consecutive trading days and after two years of continuous service as CEO, or less in the event of a change in control.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.47%
Tags
insider

FAQ

How many Alkermes plc. (ALKS) SEC filings are available on StockTitan?

StockTitan tracks 132 SEC filings for Alkermes plc. (ALKS), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Alkermes plc. (ALKS)?

The most recent SEC filing for Alkermes plc. (ALKS) was filed on November 12, 2026.